HeartFlow’s platform can create a detailed 3D model of the arteries. Credit: ustas7777777 / Shutterstock.

HeartFlow has launched the next-generation interactive HeartFlow Plaque Analysis platform, which is designed to enhance clinical decision-making in assessing patient risk in suspected coronary artery disease (CAD).

The advanced tool integrates with FFRᴄᴛ to offer a comprehensive view of a patient’s plaque burden, enabling personalised treatment plans.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

The new HeartFlow Plaque Analysis platform provides clinicians with a non-invasive solution to quantify and characterise plaque in the coronary arteries.

By analysing CT angiogram (CCTA) scans, the platform creates a detailed 3D model of the arteries, offering insights into the volume and type of plaque present.

The integration of plaque quantification with lesion-specific FFRᴄᴛ values is a key feature of the interactive experience.

It presents a 3D plaque model and comprehensive analysis, covering various plaque types such as calcified, non-calcified, and low attenuation.  

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The platform allows for displaying cross-sectional, colour-coded images of each plaque type along the vessel.

HeartFlow said the Plaque Analysis is recognised for its high level of accuracy, with a 95% agreement for total plaque volume measures when compared to the gold standard IVUS.

HeartFlow chief medical officer Campbell Rogers said: “Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment. Our new interactive plaque experience marks an exciting era in AI-enabled cardiac technology, where we are now the only company that offers a fully integrated view of a patient’s true burden of coronary artery disease.

“The elevated visualisation of Plaque Analysis integrated with our flagship FFRᴄᴛ Analysis, sets HeartFlow apart as a wholistic solution for CT analysis, enabling physicians to enhance personalised treatment decisions.”